Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KH631 Gene Therapy in nAMD
NCT05672121Phase 2Recruiting
- Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of KH631 in neovascular age-related macular degeneration (NVAMD), sponsored by Chengdu Origen Biotechnology Co., Ltd.. Started Feb 2023; status: recruiting.
02
Drugs
KH631
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05672121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05672121.